Beijing Biostar Pharmaceuticals Co., Ltd. (HKG:2563)

Hong Kong · Delayed Price · Currency is HKD

4.300

-0.530 (-10.97%)

Oct 8, 2026, 3:55 PM HKT

Market Cap	1.68B -45.4%
Revenue (ttm)	63.74M +3.1%
Net Income	-120.05M
EPS	-0.33
Shares Out	389.59M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,600
Open	4.400
Previous Close	4.830
Day's Range	4.300 - 4.400
52-Week Range	2.400 - 8.790
Beta	-0.51
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 26, 2026

About HKG:2563

Beijing Biostar Pharmaceuticals Co., Ltd., a synthetic biology-driven biopharmaceutical company, engages in the development, manufacturing, and commercialization of oncology products in the People’s Republic of China. The company develops Utidelone injections for metastatic breast cancer, breast cancer neoadjuvant, non-small cell lung cancer, pancreatic cancer, non-small cell lung cancer brain metastasis, and breast cancer brain metastasis indications; and Utidelone capsules for metastasis breast cancer, triple-negative breast cancer adjuvant i... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2002

Employees 127

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2563

Full Company Profile

Financial Performance

In 2025, HKG:2563's revenue was 33.36 million, a decrease of -53.57% compared to the previous year's 71.87 million. Losses were -131.44 million, -8.58% less than in 2024.

Financial numbers in CNY Financial Statements